DFE Pharma launches MCC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DFE Pharma launches MCC


As of February 2013 DFE Pharma offers two grades of Microcrystalline Cellulose (MCC) - Pharmacel® 101 and Pharmacel® 102 - to its global customers. MCC is, together with lactose and superdisintegrants, one of the most commonly used diluents in drug formulations. These three key excipients are now available from one single supplier DFE Pharma, unlocking potential synergies for you.

In December 2011, DFE Pharma completed the acquisition of Brahmar Cellulose Products Private Limited (BCPL), one of India’s leading excipient producers. After a successful period of consolidation, BCPL is now a fully integrated part of the global DFE Pharma organisation. We believe this gives us additional capability to serve our customers even better than before. The BCPL acquisition allowed DFE Pharma to significantly broaden its excipients portfolio with world-class MCC products.

The MCC global market introduction is an exciting move that enables us to build on a combination of strengths, further widening our portfolio and taking an important step in our pursuit of excipient excellence. All our capabilities, quality standards and support services apply as much to MCC as to our other products. We continue to develop and produce the best possible excipient solutions for our customers and look forward to serving you in the future with reliable solutions in pharmaceutical excipients.

DFE Pharma

www.dfepharma.com

pharma@dfepharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here